UroGen Pharma (URGN) earnings, Aug 5, 2026: EPS +73%, stock +16.3%
In brief
UroGen Pharma reported on Aug 5, 2026. Earnings per share changed +73% year over year, 5.7% below the estimate; revenue +199%. The stock opened with a +5.6% gap and closed the day +16.3% (Aug 5, 2026). The stock is now 49.4% below its 52-week high, +33.2% over 12 months. Next report: Mar 18, 2027.
EPS vs estimate−5.7%
EPS, YoY+73%
Revenue, YoY+199%
Gap · day+5.6% · +16.3%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Aug 5, 2026 | +5.6% | +16.3% |
Next-quarter estimates, ratings and the URGN chart are in the terminal.
Open the terminalFAQ
When is UroGen Pharma's next earnings report?
Mar 18, 2027. The date comes from daily data and is corrected if the company moves it.
How did UroGen Pharma stock react to the report?
Opening gap +5.6%, day's result +16.3%.
Did UroGen Pharma's earnings grow?
Earnings per share rose 73% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.